


**REMARKS**

It has come to the attention of the undersigned that the Amendment submitted on August 27, 2008 contains an error. Specifically, in the first full paragraph on page 8 of the Amendment, it is stated that Appendix E shows a comparison between treatment with lapatinib at a dose of 1500 mg per day and treatment with a combination of lapatinib at 1000 mg per day and pazopanib at 800 mg per day. In fact, the dosage for pazopanib in the combination treatment was 400 mg per day. Applicants' representative apologizes for any inconvenience caused by this error.

Applicants believe that all claims are in condition for allowance and such action is respectfully requested. Applicants believe that no other fees are due in connection with the filing of this paper other than those specifically authorized herewith.

Should any other fees be deemed necessary to effect the timely filing of this paper, the Commissioner is hereby authorized to charge such fees to Deposit Account No. 07-1392. If the Examiner has any outstanding issues with the pending claims, she is encouraged to telephone the undersigned at (919) 483-1467 for expeditious handling.

Respectfully submitted,



Kathryn L. Coulter  
Attorney for Applicant  
Registration No. 45,889

Date: 8/27/2008  
Customer No. 23347  
GlaxoSmithKline  
Corporate Intellectual Property  
Five Moore Drive, P.O. Box 13398  
Research Triangle Park, NC 27709-3398  
Telephone: (919) 483-1467  
Facsimile: (919) 483-7988